Author: Liu, Lixin; Liu, Zhijia; Chen, Haolin; Liu, Hong; Gao, Qiang; Cong, Feng; Gao, Guangxia; Chen, Yongming
Title: Subunit Nanovaccine with Potent Cellular and Mucosal Immunity for COVID-19 Cord-id: r0lfot3w Document date: 2020_8_18
ID: r0lfot3w
Snippet: [Image: see text] To combat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, we formulated the S1 subunit of the virus with two adjuvants, amphiphilic adjuvant monophosphoryl lipid A for Toll-like receptor 4 and CpG oligodeoxynucleotide for Toll-like receptor 9, into cationic liposomes to produce a potent, safer, and translatable nanovaccine. The nanovaccine can efficiently elicit a humoral immune response and strong IgA antibodies in mice. The sera from the vaccinated
Document: [Image: see text] To combat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, we formulated the S1 subunit of the virus with two adjuvants, amphiphilic adjuvant monophosphoryl lipid A for Toll-like receptor 4 and CpG oligodeoxynucleotide for Toll-like receptor 9, into cationic liposomes to produce a potent, safer, and translatable nanovaccine. The nanovaccine can efficiently elicit a humoral immune response and strong IgA antibodies in mice. The sera from the vaccinated mice significantly inhibit SARS-CoV-2 from infecting Vero cells. Moreover, relative to the free S1 with a traditional Alum adjuvant, the nanovaccine can elicit strong T-cell immunity by activating both CD4(+) and CD8(+) cells.
Search related documents:
Co phrase search for related documents- acute sars cov respiratory syndrome coronavirus and adjuvant protein antigen: 1
- acute sars cov respiratory syndrome coronavirus and lung lavage: 1, 2, 3, 4
- acute sars cov respiratory syndrome coronavirus and lung lavage fluid: 1, 2, 3, 4
- acute sars cov respiratory syndrome coronavirus and lysis buffer: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date